2016-04-13T15:13:41Z
2016-04-13T15:13:41Z
2013
2016-04-13T15:13:46Z
Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.
Article
Published version
English
Staphylococcus aureus; Unitats de cures intensives; Infeccions respiratòries; Staphylococcus aureus; Intensive care units; Respiratory infections
Public Library of Science (PLoS)
Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0059215
PLoS One, 2013, vol. 8, num. 3
http://dx.doi.org/10.1371/journal.pone.0059215
cc-by (c) Sierra, J.M. et al., 2013
http://creativecommons.org/licenses/by/3.0/es